Injection molded medical devices manufactured from high molecular weight polyethylene

Abstract

The high molecular weight polyethylene polymer is formulated to allow the polymer to be injection molded. The polyethylene polymer has a viscosity number greater than about 400 mL / g and a melt flow rate greater than about 0.9 g / 10 min. The polyethylene polymer is of high purity and is particularly well suited for producing medical products.

Description

[Technical field]

[0001]

[0001] This application is based on and claims priority to U.S. Provisional Patent Application No. 62 / 823,166, having a filing date of March 25, 2019, which is incorporated herein by reference. [Background technology]

[0002] Polyethylene has become established as a highly useful engineering material in a variety of applications, in part due to its unique combination of desirable properties. For example, high molecular weight polyethylene polymer particles can exhibit improved abrasion resistance, chemical resistance, lubricity, impact strength, stress crack resistance, heat deflection temperature, abrasion resistance, and energy absorption capacity at high stress rates, as compared to other thermoplastic polymers.

[0003]

[0003] High molecular weight polyethylene polymers generally include linear polyethylene polymers and can be distinguished from other polyethylene grades by their very high degree of polymerization. In fact, the high degree of polymerization is the reason why these polymers do not flow well when melted and can actually exhibit a melt flow index of 0 grams / 10 minutes. Therefore, special processing methods such as pressure sintering and ram extrusion are used to mold these polymers into articles.

[0004] However, such high molecular weight polyethylene polymers have a variety of excellent properties that make them desirable for many applications. For example, high molecular weight polyethylene polymers can have very high impact strength that is retained even at very low temperatures. In fact, high molecular weight polyethylene polymers can be made that do not break when subjected to a notched impact strength test according to ISO Test 179.

[0005]

[0005] High molecular weight polyethylene polymers also have a relatively wide operating temperature range and are very wear resistant. Furthermore, high molecular weight polyethylene has great wear resistance that can be as good as or better than steel.

[0006]

[0006] High molecular weight polyethylene polymers can also be made to be biocompatible, and thus have been used to make a variety of medical devices, such as orthopedic implants. Summary of the Invention [Problem to be solved by the invention]

[0007]

[0007] However, there is a need for high molecular weight polyethylene polymers that can be injection molded to make medical products. For example, the ability to injection mold high molecular weight polyethylene polymers may allow the polymer to be used to make smaller medical devices or otherwise more efficiently make a variety of different types of medical products. Thus, there is a need for high molecular weight polyethylene polymers that can be injection molded that still retain many of the properties exhibited by low flow polyethylene polymers. [Means for solving the problem]

[0008]

[0008] The present invention generally relates to high molecular weight polyethylene polymer compositions that are well suited for manufacturing medical products. For example, the high molecular weight polyethylene polymers are biocompatible and can be used for all different types of medical applications, including implants, prosthetic organs, drug delivery devices, and the like. In accordance with the present invention, the high molecular weight polyethylene polymers are formulated to have sufficient melt flow properties to allow the polymer to be used in an injection molding process to manufacture the medical products.

[0009] For example, in one embodiment, the present invention relates to a medical device comprising an injection molded polymeric article. The polymeric article comprises a high molecular weight polyethylene polymer. The high molecular weight polyethylene polymer has a melt flow index greater than about 0.8 g / 10 min, e.g., greater than about 0.9 g / 10 min, and generally less than about 3 g / 10 min, e.g., less than about 2 g / 10 min, when measured according to ISO test 1133 at 190° C. and a load of 21.6 kg. The high molecular weight polyethylene polymer also has a melt flow index greater than about 400 cm when tested according to ISO test 1628-3. 3 / g, e.g., about 500 cm 3 / g, generally about 900 cm 3 The high molecular weight polyethylene polymer may have a viscosity number of about 0.93 to about 0.97 g / cm when tested according to ISO test 1183-1, method A. The high molecular weight polyethylene polymer may have a molecular weight of, for example, greater than about 350,000 g / mole, for example, from about 500,000 g / mole to about 5,000,000 g / mole. As used herein, molecular weight is determined according to ASTM test D4020. The high molecular weight polyethylene polymer may have a viscosity number of about 0.93 to about 0.97 g / cm when tested according to ISO test 1183-1, method A. 3 may have a specific gravity of

[0010]

[0010] The high molecular weight polyethylene polymer is biocompatible and can be manufactured to meet the testing requirements of ISO Test 10993. For example, the high molecular weight polyethylene polymer can pass ISO Test 10993-11 for systemic toxicity, can pass ISO Test 10993-10 for intradermal reactivity, can pass ISO Test 10993-6 for 2-week muscle implantation, can pass ISO Test 10993-5 for cytotoxicity, can pass ISO Test 10993-3 for genotoxicity, can pass ISO Test 10993-4 for hemolysis, and can pass USP Test 661 for physicochemical properties.

[0011] The polymeric article of the present invention can be made primarily from high molecular weight polyethylene polymer. For example, the polymeric article can include more than about 70% by weight, such as more than about 80% by weight, such as more than about 90% by weight, such as more than about 95% by weight of high molecular weight polyethylene polymer. The high molecular weight polyethylene polymer can be a homopolymer or can include a copolymer. For example, in one embodiment, the high molecular weight polyethylene polymer can be a copolymer of ethylene and at least one monomer including propylene, butylene, or a mixture thereof. In one embodiment, the high molecular weight polyethylene polymer can be used to make an article and then crosslinked.

[0012]

[0012] The polymeric article may include various other components in addition to the high molecular weight polyethylene polymer. For example, the polymeric article may include active pharmaceutical ingredients, contrast agents, reinforcing materials, and the like.

[0013]

[0013] All different types of medical devices can be manufactured from the present high molecular weight polyethylene polymer. For example, the medical device can include a prosthesis or an implant. In one embodiment, the medical device can have a tubular shape for carrying a fluid or for covering an electrical element such as a wire.

[0014] In one embodiment, the polymeric article can be incorporated into a chip, an RFID device, a pump, a surgical instrument, or a neurostimulator. In other embodiments, the polymeric article can include a feeding tube, a catheter, an expandable balloon, a stent, a heart valve, a cochlear implant, a cranio-maxillofacial implant, a synthetic cartilage, a gastric ring, a vascular clamp, an aneurysm clip, a spinal plug, a base plate stem cap for an artificial joint, a muscle implant, a nasopharyngeal implant, a laryngeal implant, an oral mucosal insert, an intrauterine contraceptive device, an intravaginal ring, or a dental fabric. In yet another embodiment, the medical device can include a drug delivery device, a transdermal patch, or a subcutaneous implant.

[0015] The present invention also relates to a method for injection molding a medical product.In yet another embodiment, the present invention relates to a method for implanting the above-described medical device in a patient. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016]

[0016] Other features and aspects of the present invention are discussed in more detail below.

[0017] Those skilled in the art will appreciate that this discussion is merely a description of exemplary embodiments and is not intended as limiting the broader aspects of the invention.

[0017]

[0018] Generally, the present invention relates to a polyethylene composition comprising a high molecular weight polyethylene polymer that is not only biocompatible but also melt processable by injection molding. The polyethylene polymer composition is well suited for producing all different types of medical products. Because the polymer composition can be injection molded, the polyethylene polymer composition is particularly well suited for producing miniature medical devices or other medical articles where injection molding offers advantages in terms of production efficiency or offers various other benefits and advantages.

[0018]

[0019] The polyethylene polymer present in the polymer composition has a molecular weight as high as possible while still being capable of injection molding.For example, the polyethylene polymer is a high molecular weight polyethylene polymer with a melt flow rate of at least about 0.5g / 10min, for example at least about 0.7g / 10min, for example at least about 0.9g / 10min, for example at least about 1.1g / 10min, for example at least about 1.3g / 10min, and generally less than about 2.5g / 10min, for example less than about 2.3g / 10min, for example less than about 2g / 10min, for example less than about 1.8g / 10min.Melt flow index is measured according to ISO test 1133 at a temperature of 190°C and a load of 21.6kg.

[0019]

[0020] The high molecular weight polyethylene polymer is of high purity and is biocompatible. More particularly, the polyethylene polymer in the composition of the present invention passes at least most of the requirements of ISO test 10993. For example, the polyethylene polymer passes ISO test 10993-11 for systemic toxicity, ISO test 10993-10 for intradermal reactivity, ISO test 10993-6 for 2-week muscle implantation, ISO test 10993-5 for cytotoxicity, ISO test 10993-3 for genotoxicity, ISO test 10993-4 for hemolysis, and USP test 661 for physicochemical properties.

[0020]

[0021] The high molecular weight polyethylene may be a homopolymer, a copolymer, or a blend thereof, hi one embodiment, the polyethylene may be a homopolymer.

[0022] In another embodiment, the polyethylene may be a copolymer. For example, the polyethylene may be a copolymer of ethylene and other olefins containing 3 to 16 carbon atoms, such as 3 to 10 carbon atoms, such as 3 to 8 carbon atoms. These other olefins include, but are not limited to, propylene, 1-butene, 1-pentene, 1-hexene, 1-heptene, 1-octene, 4-methylpent-1-ene, 1-decene, 1-dodecene, 1-hexadecene, and the like. Polyene comonomers such as 1,3-hexadiene, 1,4-hexadiene, cyclopentadiene, dicyclopentadiene, 4-vinylcyclohex-1-ene, 1,5-cyclooctadiene, 5-vinylidene-2-norbornene, and 5-vinyl-2-norbornene may also be utilized in the present invention. However, if present, the amount of one or more non-ethylenic monomers in the copolymer may be less than about 10 mol %, such as less than about 5 mol %, for example less than about 2.5 mol %, for example less than about 1 mol %, where mol % is based on the total moles of monomers in the polymer.

[0021]

[0023] In one embodiment, the polyethylene may exhibit a bimodal molecular weight distribution. For example, a bimodal distribution generally refers to a polymer having a separate higher molecular weight and a separate lower molecular weight (e.g., two separate peaks) on a gel permeation chromatography curve. In other embodiments, the polyethylene may exhibit more than two molecular weight distribution peaks such that the polyethylene exhibits a multimodal (e.g., trimodal, tetramodal, etc.) distribution. Alternatively, the polyethylene may exhibit a broad molecular weight distribution in which the polyethylene is composed of a blend of higher and lower molecular weight components such that a size exclusion chromatography or gel permeation chromatography curve does not exhibit at least two separate peaks, but instead exhibits one separate peak that is broader than the individual component peaks.

[0022]

[0024] In one embodiment, the composition may be comprised of more than one polyethylene polymer, each having a different molecular weight and / or molecular weight distribution, for example, the molecular weight distribution may be within the average molecular weight specifications given above.

[0023]

[0025] Additionally, the composition may be comprised of a blend of one or more polyethylene polymers or copolymers with other thermoplastic polymers such as polypropylene or polybutylene, however, the amount of non-polyethylene polymer(s) in the composition may be less than about 10% by weight, such as less than about 5% by weight, such as less than about 2.5% by weight, such as less than about 1% by weight, where the weight percent is based on the total weight of the composition.

[0024]

[0026] Any method known in the art can be utilized to synthesize polyethylene. High molecular weight polyethylene powders are typically produced by catalytic polymerization of ethylene monomer, and optionally one or more other 1-olefin comonomers, with the 1-olefin content in the final polymer being less than 10% of the ethylene content, with a heterogeneous catalyst and an organoaluminum or magnesium compound as a cocatalyst. Ethylene is typically polymerized in gas or slurry phase at relatively low temperatures and pressures. The polymerization reaction can be carried out at temperatures between 50°C and 100°C, and pressures ranging from 0.02 to 2 MPa.

[0025]

[0027] The molecular weight of the polyethylene can be adjusted by adding hydrogen. Changes in temperature and / or type and concentration of cocatalyst can be used to fine-tune the molecular weight. Additionally, the reaction can be carried out in the presence of antistatic agents to avoid wall fouling and product contamination.

[0026]

[0028] Suitable catalyst systems include, but are not limited to, Ziegler-Natta type catalysts. Typically, Ziegler-Natta type catalysts are derived from the combination of a transition metal compound from Groups 4-8 of the Periodic Table with an alkyl or hydrogenated derivative of a metal from Groups 1-3 of the Periodic Table. The transition metal derivatives used usually include metal halides or esters or combinations thereof. Representative Ziegler-Natta catalysts include those based on the reaction products of, for example, aluminum or magnesium alkyls and organoaluminum or magnesium compounds such as, but not limited to, titanium, vanadium, or chromium halides or esters. Heterogeneous catalysts may be unsupported or supported on porous particulate materials such as silica or magnesium chloride. Such supports may be added during the synthesis of the catalyst or may be obtained as a chemical reaction product of the catalyst synthesis itself.

[0027]

[0029] In one embodiment, a suitable catalyst system can be obtained by reacting a titanium(IV) compound with a trialkylaluminum compound in an inert organic solvent at a temperature ranging from -40°C to 100°C, preferably from -20°C to 50°C. The concentrations of the starting materials are in the range of 0.1 to 9 mol / L, preferably 0.2 to 5 mol / L for the titanium(IV) compound and 0.01 to 1 mol / L, preferably 0.02 to 0.2 mol / L for the trialkylaluminum compound. The titanium component is added to the aluminum component over a period of 0.1 to 60 minutes, preferably 1 to 30 minutes, and the molar ratio of titanium to aluminum in the final mixture is in the range of 1:0.01 to 1:4.

[0028]

[0030] In another embodiment, a suitable catalyst system is obtained by one or two step reaction of a titanium(IV) compound with a trialkylaluminum compound in an inert organic solvent at a temperature ranging from -40°C to 200°C, preferably from -20°C to 150°C. In the first step, the titanium(IV) compound is reacted with the trialkylaluminum compound at a temperature ranging from -40°C to 100°C, preferably from -20°C to 50°C, using a titanium:aluminum molar ratio ranging from 1:0.1 to 1:0.8. The concentrations of the starting materials range from 0.1 to 9.1 mol / L, preferably from 5 to 9.1 mol / L for the titanium(IV) compound and from 0.05 to 1 mol / L, preferably from 0.1 to 0.9 mol / L for the trialkylaluminum compound. The titanium component is added to the aluminum compound over a period of 0.1 to 800 minutes, preferably from 30 to 600 minutes. If applicable, in the second step, the reaction product obtained in the first step is treated with a trialkylaluminum compound at a temperature ranging from -10°C to 150°C, preferably from 10°C to 130°C, using a titanium:aluminum molar ratio ranging from 1:0.01 to 1:5.

[0029]

[0031] In yet another embodiment, a suitable catalytic system is obtained by a procedure in which in a first reaction step, magnesium alcoholate is reacted with titanium chloride in an inert hydrocarbon at a temperature between 50° C. and 100° C. In a second reaction step, the reaction mixture formed is subjected to a heat treatment at a temperature between 110° C. and 200° C. for about 10 to 100 hours while generating alkyl chlorides until no further alkyl chlorides are generated, and then the solid is liberated from the soluble reaction products by washing several times with a hydrocarbon.

[0030]

[0032] In a further embodiment, a catalyst supported on silica such as, for example, the commercially available catalyst system Sylopol 5917 may be used.

[0033] With such a catalyst system, the polymerization is usually carried out in suspension, at low pressure and low temperature, in one or more steps, continuous or batchwise. The polymerization temperature is usually in the range of 30°C to 130°C, preferably in the range of 50°C to 90°C, and the ethylene partial pressure is usually less than 10 MPa, preferably 0.05 to 5 MPa. Trialkylaluminum, such as but not limited to isoprenylaluminum and triisobutylaluminum, is used as the cocatalyst, with an Al:Ti (cocatalyst:catalyst) ratio in the range of 0.01 to 100:1, more preferably in the range of 0.03 to 50:1. The solvent is an inert organic solvent usually used for Ziegler type polymerization. Examples are butane, pentane, hexane, cyclohexene, octane, nonane, decane, their isomers, and mixtures thereof. The molecular weight of the polymer is controlled by feeding hydrogen. The ratio of hydrogen partial pressure to ethylene partial pressure is in the range of 0 to 50, preferably in the range of 0 to 10. The polymer is isolated and dried in a fluid bed dryer under nitrogen. The solvent can be removed by steam distillation if a high boiling solvent is used. Salts of long chain fatty acids can be added as stabilizers. Typical examples are calcium stearate, magnesium stearate, and zinc stearate.

[0031]

[0034] Other catalysts such as Phillips catalysts, metallocenes, and post-metallocenes can be used in some cases. Generally, cocatalysts such as alumoxanes or alkylaluminum or alkylmagnesium compounds are also used. For example, Fritzsche et al., U.S. Patent Application Publication No. 2002 / 0040113 (the entire contents of which are incorporated herein by reference), discusses several catalyst systems for producing high molecular weight polyethylene. Other suitable catalyst systems include Group 4 metal complexes of phenolate ether ligands, as described in International Patent Publication No. WO2012 / 004675 (the entire contents of which are incorporated herein by reference).

[0032]

[0035] The polyethylene used in the present invention may have an average molecular weight, determined according to ASTM test D4020, of at least 100,000 g / mol or more, such as at least about 200,000 g / mol, for example at least about 300,000 g / mol, such as at least about 350,000 g / mol, for example at least about 450,000 g / mol, such as at least about 500,000 g / mol, for example at least about 600,000 g / mol, such as higher than about 1,000,000 g / mol, for example higher than about 1,500,000 g / mol, such as higher than about 2,000,000 g / mol, typically less than about 5,000,000 g / mol, such as less than about 3,000,000 g / mol, for example less than about 1,000,000 g / mol. For example, the average molecular weight of the polymer may be greater than about 300,000 g / mol and less than about 5,000,000 g / mol, including all increments of 25,000 g / mol therebetween.

[0033]

[0036] Polyethylene can be produced in the form of a powder, such as a micropowder. For example, the polyethylene powder can be a free-flowing powder. The polyethylene powder can have a multi-lobed (popcorn-like) morphology. The powder can have an average particle size d50 of 2,000 μm or less, such as about 10 to about 1,500 μm, such as about 50 μm to about 650 μm, such as about 50 to about 400 μm, such as about 50 to about 200 μm. Preferably, the as-synthesized polymer has the desired particle size. However, if the as-synthesized polymer has a particle size larger than the desired value, the particles can be ground to the desired particle size. The particle size of the powder can be measured using a laser diffraction method according to ISO-13320.

[0034]

[0037] The polyethylene may have a viscosity number of at least 100 mL / g, such as at least 200 mL / g, for example at least 300 mL / g, such as at least 400 mL / g, for example at least 500 mL / g, to less than about 2,000 mL / g, such as less than about 1,500 mL / g, for example less than about 1,000 mL / g, such as less than about 800 mL / g, for example less than about 600 mL / g, determined according to ISO-1628-Part 3 using a concentration in decahydronaphthalene of 0.0002 g / mL.

[0035]

[0038] The polyethylene can be present in the composition in an amount of more than about 70% by weight, for example more than about 75% by weight, for example more than about 80% by weight, for example more than about 85% by weight, for example more than about 90% by weight, for example more than about 95% by weight, for example more than about 98% by weight, but less than about 100% by weight, for example less than about 98% by weight, for example less than about 95% by weight. The above amounts can refer to a single high molecular weight polyethylene polymer or to a blend of multiple high molecular weight polyethylene polymers. However, in one embodiment, only a single high molecular weight polyethylene polymer is used to produce the polymer article.

[0036]

[0039] As noted above, the high molecular weight polyethylene polymer is generally of high purity. In this regard, the high molecular weight polyethylene polymer may have an ash content of less than about 500 ppm, such as less than about 250 ppm, such as less than about 100 ppm, such as less than about 50 ppm, such as less than about 10 ppm. The high molecular weight polyethylene polymer generally has an ash content of less than about 0.93 g / cm when tested according to ISO test 1183. 3 Larger, for example about 0.94 g / cm 3 Larger, for example about 0.95 g / cm 3 Larger, typically around 0.97 g / cm 3 It may have a specific gravity of less than 1.5.

[0037]

[0040] The polymer compositions and polymeric articles made therefrom may also include other known additives such as, for example, antioxidants, UV stabilizers, light stabilizers, heat stabilizers, reinforcing fibers or fillers, lubricants, optical brighteners, colorants, mold release agents, crosslinking agents, plasticizers, pigments, antistatic agents, etc. In one embodiment, all polymeric additives present in the polymeric article are biocompatible.

[0038]

[0041] Antioxidants, in some embodiments, can reduce oxidation and / or chemical degradation of the polyethylene compositions described herein during storage, transportation, and / or packaging (in vivo and / or ex vivo). Examples of antioxidants suitable for use in combination with the polyethylene compositions described herein, in some embodiments, can include, but are not limited to, ascorbic acid, glutathione, lipoic acid, uric acid, resveratrol, flavonoids, carotenes (e.g., β-carotene), carotenoids, tocopherols (e.g., α-tocopherol), tocotrienols, ubiquinol, melatonin, secondary aromatic amines, benzofuranones, hindered phenols, polyphenols, hindered amines, organophosphorus compounds, thioesters, benzoates, lactones, hydroxylamines, and any combination thereof.

[0039]

[0042] Reinforcing fillers can, among other things, increase the mechanical strength of the polyethylene compositions described herein in some embodiments. Examples of reinforcing fillers suitable for use in combination with the polyethylene compositions described herein can include, but are not limited to, glass spheres, glass fibers, bioglass, graphite, aluminum powder, talc, chalk, silicates, carbonates, calcium carbonate, alumina trihydrate, marble dust, cement dust, clay, feldspar, fumed silica, alumina, magnesium oxide, magnesium hydroxide, antimony oxide, zinc oxide, barium sulfate, aluminum silicate, calcium silicate, titanium dioxide, titanates, glass microspheres, carbon fibers, metal fibers, carbon nanotubes, wood flour, carbon black, and the like, and any combination thereof.

[0040]

[0043] Examples of pigments and / or dyes suitable for use in combination with the polyethylene compositions described herein, in some embodiments, can include, but are not limited to, inorganic colorants, organic colorants, and the like, and any combination thereof.

[0041]

[0044] Examples of anti-fouling agents suitable for use in combination with the polyethylene compositions described herein, in some embodiments, can include, but are not limited to, sulfonamides, penicillins, cephalosoline, carbapenems, quinolones, oxazolidones, quaternary ammonium compounds, precious metals (e.g., silver, gold, copper, etc.), amine-containing polymers, and the like, and any combination thereof.

[0042]

[0045] These additives can be used alone or in any combination thereof. Generally, unless otherwise indicated, when additives are used, they can be present in an amount of at least about 0.05% by weight, such as at least about 0.1% by weight, such as at least about 0.25% by weight, such as at least about 0.5% by weight, such as at least about 1% by weight, and generally less than about 20% by weight, such as less than about 10% by weight, such as less than about 5% by weight, such as less than about 4% by weight, such as less than about 2% by weight. The sum of the weight percentages of all components, including additives, if present, is 100% by weight.

[0043]

[0046] In one embodiment, the polyethylene polymer composition can include an active pharmaceutical ingredient and / or at least one imaging agent. The active pharmaceutical ingredient can be surface coated onto the polymer article or can be homogeneously mixed with the polymer. In general, any suitable active pharmaceutical ingredient can be incorporated into the polymer article.

[0044]

[0047] Contrast agents that interact with electromagnetic radiation can also be incorporated into the polymeric article, allowing the polymeric article to be better identified by X-ray or other imaging systems. Examples of contrast agents suitable for use in combination with the polyethylene compositions described herein include, in some embodiments, but are not limited to, magnetic resonance contrast agents (e.g., barium sulfate, iron oxide particles, gadolinium compounds, erbium compounds, gadolinium endofullerenes, and gadolinium endo nanotubes), x-ray contrast agents (e.g., barium sulfate, iodine compounds, and iodine endo nanotubes), ultrasound contrast agents (e.g., perfluorocarbons and bubbles), near-infrared contrast agents (e.g., carbon nanotubes, gold nanoparticles, silver nanoparticles, and gold nanoshells), bismuth compounds, tungsten compounds, and the like, and any combination thereof. In general, the contrast agent can be present in the polymeric composition in an amount of about 0.01% to about 5% by weight.

[0045]

[0048] The polymer compositions of the present invention can be used to manufacture many different types of medical products. For example, the polyethylene polymer compositions can be used to manufacture prostheses, implants, etc. The polymer compositions can also be used to manufacture medical devices and all different types of tubular devices such as catheters, inhalers, etc.

[0046]

[0049] Examples of medical products that can be manufactured according to the present invention include, but are not limited to, chips, RFID tags, tubes, pumps, feeding tubes, catheters, vascular catheters, prostheses, expandable balloons, stents, heart valves, neurostimulators, cochlear implants, cranio-maxillofacial implants, synthetic cartilage, gastric rings, surgical instruments, vascular clamps, aneurysm clamps, spinal plugs for use in conjunction with joint fusion systems, base plates for use in artificial joints, muscle implants, nasopharyngeal implants, laryngeal implants, drug delivery devices, transdermal patches, subdermal implants, oral mucosal inserts, intrauterine contraceptive devices, intravaginal rings, dental textiles, hip implants, tibial implants, wrist implants, hand implants, parts thereof, and the like.

[0047]

[0050] In some embodiments, the molded polyethylene parts of the present invention comprise at least one wall defining an interior volume, where the at least one wall may be a conduit comprising a polyethylene composition described herein.

[0048]

[0051] In some embodiments, the conduit molded polyethylene parts can be designed to allow fluid to flow through an interior volume. For example, biomedical devices such as pumps, tubes, feeding tubes, catheters, vascular catheters, stents, heart valves, surgical instruments (e.g., surgical suction instruments), nasopharyngeal implants, and laryngeal implants can each include at least one conduit molded polyethylene part designed to allow fluid to flow through an interior volume.

[0049]

[0052] In some embodiments, the conduit molded polyethylene component can have at least one wire disposed within the interior volume. By way of non-limiting example, in some embodiments, a biomedical device (e.g., a pacemaker) can include at least one wire having a conduit molded polyethylene component disposed nearby.

[0050]

[0053] In some embodiments, the molded polyethylene parts described herein may be the main components of a biomedical device (e.g., a cranio-maxillofacial implant). In some instances, the polyethylene component of the molded polyethylene part may include polyethylene and a bioabsorbable polymer such that upon installation, the bioabsorbable polymer is absorbed leaving voids in the polyethylene composition.

[0051]

[0054] In some embodiments, the molded polyethylene parts of the present invention may substantially encase other components of a biomedical device. In some embodiments, the encasement may be such that when implanted in a patient, the surrounding tissues are primarily exposed to the molded polyethylene part. In some embodiments, the encasement may be achieved by overmolding, thermoforming, or shrink wrapping the polyethylene compositions described herein around the other components that are to be at least partially encased. In some embodiments, the encasement may be achieved by forming a molded polyethylene part appropriately dimensioned for placement of the biomedical device and / or components thereof therein.

[0052]

[0055] As a non-limiting example, in some embodiments, a biomedical device, such as a cochlear implant or an RFID tag, can be substantially encapsulated in a molded polyethylene part such that the molded polyethylene part substantially approximates a coating disposed about the biomedical device. As another non-limiting example, a biomedical device, such as a pacemaker or neurostimulator, can include a molded polyethylene part that includes a wire having a coating disposed substantially thereabout, the coating comprising a polyethylene composition described herein. As another non-limiting example, a power source for a neurostimulator can include a molded polyethylene part that substantially encapsulates the power source, achieved, for example, by overmolding, thermoforming, or shrink wrapping.

[0053]

[0056] In some embodiments, the molded polyethylene parts described herein may be a drug delivery device or part thereof. In some embodiments, the transdermal patch may include a backing, a medicated layer, and a release layer, where the molded polyethylene component may be the medicated layer and / or the release layer. As a non-limiting example, the medicated layer may be a molded polyethylene part and the release layer may include a second polymer (e.g., an ethylene copolymer such as ethylene vinyl acetate). In some cases, the molded polyethylene part may include polyethylene and a second polymer. In some cases, the medicated layer and the release layer may be molded polyethylene parts with different compositions.

[0054]

[0057] Similar to the transdermal patch example, other drug delivery devices can include molded polyethylene components, such as vaginal rings with a core similar to the medicated layer described above and a sheath similar to the release layer described above. In another example, a subdermal implant such as a rod or sheet having a multi-layer structure can have at least one layer similar to the medicated layer and at least one layer similar to the release layer described above.

[0055]

[0058] The high molecular weight polyethylene polymer composition of the present invention can be formed into medical articles using a variety of different techniques, however, the polymer composition is particularly well suited for injection molding.

[0056]

[0059] During melt processing, the polymer composition can be heated to a temperature generally greater than about 100° C. and up to about 300° C. In one embodiment, the polymer composition can be crosslinked after forming the polymer article. For example, in one embodiment, the polymer composition can include a crosslinking agent in an amount of about 0.001% to about 1% by weight. Crosslinking agents that can be used include, for example, peroxides or silanes. The polymer can be crosslinked using electron beam crosslinking or gamma radiation. EXAMPLES

[0057]

[0060] The following examples illustrate the injection molding of polymer compositions according to the invention.

[0061] A high molecular weight polyethylene polymer is compounded according to the present invention. The high molecular weight polyethylene polymer had a melt flow rate of 1.1 g / 10 min when tested at 190° C. and a load of 21.6 kg. The polyethylene polymer had a viscosity number of 500 mL / g.

[0058]

[0062] To demonstrate that high molecular weight polymers can be injection molded, the polymers were molded into ISO tensile bars using injection molding.

[0063] During injection molding, the total shot weight was 25 grams. The injection molding machine was operated at the following temperatures: Zone 1 52°C, Zone 2 188°C, Zone 3 238°C, Zone 4 274°C, and nozzle 260°C. The mold temperature was 70°C. The injection speed was 25 mm / sec and the injection pressure was 686 bar.

[0059]

[0064] During injection molding, the hold time was 12 seconds, the cooling time was 35 seconds, the screw recovery time was 15.7 seconds, the cycle time was 63 seconds, the screw speed was 225 rpm, and the back pressure was 69 bar.

[0060]

[0065] ISO tensile bars were successfully injection molded. The tensile bars were tested for tensile stress according to ISO test 11542-2. The tensile bars had an tensile stress of less than 0.05 MPa.

[0061]

[0066] These and other modifications and variations of the present invention are within the scope of the appended claims. It should be understood that the above description is merely illustrative and is not intended to limit the scope of the invention as further described in the appended claims. The claims as filed are set forth below. [Claim 1] 1. A medical device comprising an injection molded polymeric article, the polymeric article comprising a high molecular weight polyethylene polymer, the high molecular weight polyethylene polymer having a melt flow index greater than about 0.8 g / 10 min and less than about 3 g / 10 min at 190° C. and a load of 21.6 kg as measured by ISO test 1133, the high molecular weight polyethylene having a melt flow index of greater than about 400 cm when tested according to ISO test 1628-3. 3 The medical device having a viscosity number greater than 1 / g. [Claim 2] 2. The medical device of claim 1, wherein the high molecular weight polyethylene polymer has a melt flow index of about 0.9 g / 10 min to about 2.0 g / 10 min. [Claim 3] The high molecular weight polyethylene polymer has a molecular weight of about 450 cm 3 / g, approximately 900 cm 3 The medical device according to claim 1, having a viscosity number of less than 1 / g. [Claim 4] 4. The medical device of claim 1, wherein the high molecular weight polyethylene polymer has a molecular weight greater than about 300,000 g / mol according to ASTM test D4020. [Claim 5] 5. The medical device of claim 4, wherein the high molecular weight polyethylene polymer has a molecular weight according to ASTM test D4020 of about 350,000 g / mol to about 5,000,000 g / mol. [Claim 6] The high molecular weight polyethylene polymer has a modulus of about 0.93 g / cm when tested according to ISO test 1183-1, method A. 3 ~Approx. 0.97g / cm 3 6. The medical device according to claim 1, having a specific gravity of [Claim 7] 7. The medical device of claim 1, wherein the high molecular weight polyethylene polymer meets at least some of the test requirements of ISO test 10993. [Claim 8] 8. The medical device of claim 7, wherein the high molecular weight polyethylene polymer passes ISO test 10993-11 for systemic toxicity, passes ISO test 10993-10 for intradermal reactivity, passes ISO test 10993-6 for 2-week muscle implantation, passes ISO test 10993-5 for cytotoxicity, passes ISO test 10993-3 for genotoxicity, passes ISO test 10993-4 for hemolysis, and passes USP test 661 for physicochemical properties. [Claim 9] 9. The medical device of claim 1, wherein the injection molded polymeric article comprises greater than about 70% by weight of the high molecular weight polyethylene polymer. [Claim 10] 10. The medical device of claim 1, wherein the injection molded polymeric article comprises greater than about 90% by weight of the high molecular weight polyethylene polymer. [Claim 11] 11. The medical device of claim 1, wherein the high molecular weight polyethylene polymer comprises a copolymer of ethylene and at least one monomer comprising propylene, butylene, or a mixture thereof. [Claim 12] 12. The medical device of claim 1, wherein the shaped polymeric article further comprises an active pharmaceutical ingredient. [Claim 13] The medical device of claim 1 , wherein the polymeric article further comprises a contrast agent. [Claim 14] The medical device of claim 1 , wherein the polymeric article comprises a prosthetic device. [Claim 15] The medical device of claim 1 , wherein the polymeric article comprises an implant. [Claim 16] The medical device of any one of claims 1 to 13, wherein the polymeric article has a tubular shape. [Claim 17] 14. The medical device of claim 1, wherein the polymeric article is incorporated into a chip, an RFID tag, a surgical instrument, a neurostimulator, or a pump. [Claim 18] 14. The medical device of any of claims 1 to 13, wherein the polymeric article comprises a feeding tube, a catheter, an expandable balloon, a stent, a heart valve, a cochlear implant, a cranio-maxillofacial implant, a synthetic cartilage, a gastric ring, a vascular clamp, an aneurysm clip, a spinal plug, a base plate stem cap for an artificial joint, a muscle implant, a nasopharyngeal implant, a laryngeal implant, an oral mucosal insert, an intrauterine contraceptive device, an intravaginal ring, or a dental fabric. [Claim 19] 14. The medical device of claim 1, wherein the polymeric article comprises a drug delivery device, a transdermal patch, or a subdermal implant. [Claim 20] Implanting the medical device according to any one of claims 1 to 13 into a patient; The method includes:

Claims

1. 1. A medical device comprising an injection molded polymeric article, the polymeric article comprising a high molecular weight polyethylene polymer, the high molecular weight polyethylene polymer having a melt flow index greater than about 0.8 g / 10 min and less than about 3 g / 10 min at 190° C. and 21.6 kg load as measured by ISO test 1133, the high molecular weight polyethylene having a melt flow index of greater than about 400 cm when tested according to ISO test 1628-3. ３ The medical device having a viscosity number greater than 1 / g.

2. 10. The medical device of claim 1, wherein the high molecular weight polyethylene polymer has a melt flow index of about 0.9 g / 10 min to about 2.0 g / 10 min.

3. The high molecular weight polyethylene polymer has a thickness of about 450 cm ３ / g, approximately 900 cm ３ The medical device of any of claims 1 to 2, having a viscosity number of less than 1 / g.

4. The medical device of any of claims 1 to 3, wherein the high molecular weight polyethylene polymer has a molecular weight greater than about 300,000 g / mol according to ASTM test D4020.

5. 5. The medical device of claim 4, wherein said high molecular weight polyethylene polymer has a molecular weight of about 350,000 g / mol to about 5,000,000 g / mol according to ASTM test D4020.

6. The high molecular weight polyethylene polymer has a modulus of about 0.93 g / cm when tested according to ISO test 1183-1, method A. ３ ~Approx. 0.97g / cm ３ The medical device according to any one of claims 1 to 5, having a specific gravity of

7. The medical device of any of claims 1-6, wherein the high molecular weight polyethylene polymer meets at least some of the test requirements of ISO test 10993.

8. 8. The medical device of claim 7, wherein said high molecular weight polyethylene polymer passes ISO test 10993-11 for systemic toxicity, passes ISO test 10993-10 for intradermal reactivity, passes ISO test 10993-6 for 2-week muscle implantation, passes ISO test 10993-5 for cytotoxicity, passes ISO test 10993-3 for genotoxicity, passes ISO test 10993-4 for hemolysis, and passes USP test 661 for physicochemical properties.

9. The medical device of any of claims 1 to 8, wherein the injection molded polymeric article comprises greater than about 70% by weight of the high molecular weight polyethylene polymer.

10. The medical device of any of claims 1 to 9, wherein the injection molded polymeric article comprises greater than about 90% by weight of the high molecular weight polyethylene polymer.

11. The medical device of any of claims 1-10, wherein the high molecular weight polyethylene polymer comprises a copolymer of ethylene and at least one monomer comprising propylene, butylene, or a mixture thereof.

12. The medical device of any of claims 1 to 11, wherein the shaped polymeric article further comprises an active pharmaceutical ingredient.

13. The medical device of any of claims 1 to 12, wherein the polymeric article further comprises a contrast agent.

14. The medical device of any of claims 1 to 13, wherein the polymeric article comprises a prosthetic device.

15. The medical device of any of claims 1 to 13, wherein the polymeric article comprises an implant.

16. The medical device of any of claims 1 to 13, wherein the polymeric article has a tubular shape.

17. The medical device of any of claims 1 to 13, wherein the polymeric article is incorporated into a chip, an RFID tag, a surgical instrument, a neurostimulator, or a pump.

18. 14. The medical device of any of claims 1 to 13, wherein the polymeric article comprises a feeding tube, a catheter, an expandable balloon, a stent, a heart valve, a cochlear implant, a cranio-maxillofacial implant, a synthetic cartilage, a gastric ring, a vascular clamp, an aneurysm clip, a spinal plug, a base plate stem cap for an artificial joint, a muscle implant, a nasopharyngeal implant, a laryngeal implant, an oral mucosal insert, an intrauterine contraceptive device, an intravaginal ring, or a dental fabric.

19. The medical device of any of claims 1 to 13, wherein the polymeric article comprises a drug delivery device, a transdermal patch, or a subdermal implant.

20. The medical device according to any one of claims 1 to 13, which is intended to be implanted in a patient.